Academic Journal
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
| Τίτλος: | Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial |
|---|---|
| Συγγραφείς: | Heerspink H. J. L., Agarwal R., Bakris G. L., Cherney D. Z. I., Lam C. S. P., Neuen B. L., Sarafidis P. A., Tuttle K. R., Wanner C., Brinker M. D., Dizayee S., Kolkhof P., Schloemer P., Vesterinen P., Perkovic V., Bittar J., Zaidman C. J., Cluigt N., Hominal M., Aguerre P., Halac F., Gelersztein E., Arriola M., Maldonado R., Chahin M., Packham D., Lee D., Pedagogos E., Foote C., Badve S., Hawley C., Chen J., Gray N., Speeckaert M., Labriola L., Doubel P., Maes B., Claes K., Dubois B., Dimitrova I., Vutova T., Ilchev S., Stamova S., Ivanova Y., Vasileva A., Chen X., Tang S., Xu X., Liu B., He W., He Y., Liu F., Wang C., Chen L., Niu J., Wang D., Luo P., Xia Y., Jiang G., Luo Q., Wang F., Chen M., Lin H., Yan R., Li Y., Chen Q., Dong J., Xiong F., Long H., Cheng H., Du J., Lu W., Chen C., Wang J., Liu L., Yang M., Long G., Shi Y., Li W., Yang X., Yang A., Li J., Meng X., Prazny M., Hornova L., Bucek P., Majernikova M., Wirth J., Rehorova J., Hornum M., Bech J., Lindhardt M., Hansen D., Mortensen L., Juhl C., Boletis I., Papadopoulou D., Papachristou E., Bamichas G., Petras D., Gouva C., Sarafidis P., Stylianou K., Ntounousi E., Tang S. C. W., Szeto C. C., Fung S. K. S., Lui S. L., Kovacs L., Nemeth A., Zilahi Z., Szelestei T., Kirschner R., Ignatius A., Almeida A., Sahay M., Arunkumar S., Khullar D., Pandey R., Ramanathan S., Gracious N., Mavani S., Levin-Iaina N., Rozen-Zvi B., Kruzel-Davila E., Haviv Y., Chetrit S. B., Beckerman P., Leiba A., Chernin G., Beberashvili I., Bassat O. K. -B., Kenig Y., Farber E., Ilieva A. P., Esposito C., Minutolo R., La Manna G., Santorelli G., Gregorini M. C., Donati G., Fiaccadori E., Gidaro B., Cimino R., Grandaliano G., Nakaya I., Maeda Y., Toda T., Okada H., Amemiya M., Suzuki H., Abe M., Nishi H., Kanno Y., Ueda S., Fujii T., Oshikawa J., Koizumi M., Tamura K., Yazawa M., Iwamoto T., Toyama T., Kitagawa K., Uchimura K., Kamijo Y., Ako S., Miyamoto K., Misaki T., Suzuki S., Shimizu H., Fujita Y., Ono M., Yamauchi A., Fujii H., Fujii N., Matsui M., Kidokoro K., Kanai H., Masutani K., Fujisaki K., Ishii M., Nakamura M., Toyoda M., Makita Y., Lee L. Y., Loh C. L., Yakob S., Ahmad M. K., Lee K. Q., Md Adnan W. A. H. W., Kader M. A. S. A., Ahmad N. H., Govindan S., Wahab M. Z. A., Mazlan S. A. D., Santana S. I., Wong A. C., Pardo S. A., Bayram E., Birne R., Teixeira E Costa F., Costa J. S., Alves A. R., Pereira T., Rodionova T., Antropenko N., Abissova T., Zhdanova E., Ezhov A., Suhail S. M., Liu A., Teo J., Yeo S. C., Tan N. C., Kim S., Lee K. W., Shin S. J., Han B. -G., Lee J., Han S. Y., Jang H. R., Lee J. P., Park J. T., Kang Y. S., Lee S. Y., Kim Y. C., Lee S. H., Park H., Oh J. E., Kim Y. H., Choi B. S., Segura De La Morena J. J., Jaras J. H., Deben F. M., Bouarich H., Iborra P. L., Romero M. S., Teruel J. G., Castro C., Garrit J. C., Barrios C., Chiu Y. -L., Chen H. -H., Hung C. -C., Lin S. -L., Lee C. -T., Wu M. -J., Chiu P. -F., Chang C. -T., Cheng H. -T., McCafferty K., Griffin S., Smith P., Doulton T., Pickett T., Khwaja A., Alicic R., Alla S., Anand S., Atta M., Awad A., Bansal S., Burgner A., Chang A., Christiano C., Gupta A., Hernandez G., Jamal A., Kirk E., Kopyt N., Kotzker W., Mendez R., Meyer J., Mirkhel A., Newman G., Panse S., Pergola P., Rahman M., Rastogi A., Smith M., Turner J., Umpierrez G., Vo N., Schmidt D., Frome A., Nakhoul G., Ralph R., Tolins J., Kendrick J., Quadrini M., Elahi S., Manllo S. T., Chiang W. -Y., Moussa J., Thethi T. |
| Συνεισφορές: | Heerspink, H. J. L., Agarwal, R., Bakris, G. L., Cherney, D. Z. I., Lam, C. S. P., Neuen, B. L., Sarafidis, P. A., Tuttle, K. R., Wanner, C., Brinker, M. D., Dizayee, S., Kolkhof, P., Schloemer, P., Vesterinen, P., Perkovic, V., Bittar, J., Zaidman, C. J., Cluigt, N., Hominal, M., Aguerre, P., Halac, F., Gelersztein, E., Arriola, M., Maldonado, R., Chahin, M., Packham, D., Lee, D., Pedagogos, E., Foote, C., Badve, S., Hawley, C., Chen, J., Gray, N., Speeckaert, M., Labriola, L., Doubel, P., Maes, B., Claes, K., Dubois, B., Dimitrova, I., Vutova, T., Ilchev, S., Stamova, S., Ivanova, Y., Vasileva, A., Chen, X., Tang, S., Xu, X., Liu, B., He, W., He, Y., Liu, F., Wang, C., Chen, L., Niu, J., Wang, D., Luo, P., Xia, Y., Jiang, G., Luo, Q., Wang, F., Chen, M., Lin, H., Yan, R., Li, Y., Chen, Q., Dong, J., Xiong, F., Long, H., Cheng, H., Du, J., Lu, W., Chen, C., Wang, J., Liu, L., Yang, M., Long, G., Shi, Y., Li, W., Yang, X., Yang, A., Li, J., Meng, X., Prazny, M., Hornova, L., Bucek, P., Majernikova, M., Wirth, J., Rehorova, J., Hornum, M., Bech, J., Lindhardt, M., Hansen, D., Mortensen, L., Juhl, C., Boletis, I., Papadopoulou, D. |
| Έτος έκδοσης: | 2025 |
| Συλλογή: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Θεματικοί όροι: | clinical trial, eGFR slope, finerenone, immunoglobulin A nephropathy, non-diabetic chronic kidney disease |
| Περιγραφή: | Background: Finerenone, a non-steroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes in two phase 3 outcome trials. The Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) study investigates the effect of finerenone in adults with CKD without diabetes. Methods: FIND-CKD (NCT05047263 and EU CT 2023-506897-11-00) is a randomized, double-blind, placebo-controlled phase 3 trial in patients with CKD of non-diabetic aetiology. Adults with a urinary albumin:creatinine ratio (UACR) ≥200-≤3500 mg/g and an estimated glomerular filtration rate (eGFR) ≥25-<90 ml/min/1.73 m2 receiving a maximum tolerated dose of a renin-angiotensin system inhibitor were randomized 1:1 to once-daily placebo or finerenone 10 or 20 mg depending on eGFR >60 or <60 ml/min/1.73 m2. The primary efficacy outcome is total eGFR slope, defined as the mean annual rate of change in eGFR from baseline to month 32. Secondary efficacy outcomes include a combined cardiorenal composite outcome comprising time to kidney failure, sustained ≥57% decrease in eGFR, hospitalization for heart failure or cardiovascular death, as well as separate kidney and cardiovascular composite outcomes. Adverse events are recorded to assess tolerability and safety. Results: Across 24 countries, 3231 patients were screened and 1584 were randomized to study treatment. The most common causes of CKD were chronic glomerulonephritis (57.0%) and hypertensive/ischaemic nephropathy (29.0%). Immunoglobulin A nephropathy was the most common glomerulonephritis (26.3% of the total population). At baseline, mean eGFR and median UACR were 46.7 ml/min/1.73 m2 and 818.9 mg/g, respectively. Diuretics were used by 282 participants (17.8%), statins by 851 (53.7%) and calcium channel blockers by 794 (50.1%). Sodium-glucose co-transporter 2 (SGLT2) inhibitors were used in 16.9% of patients; these ... |
| Τύπος εγγράφου: | article in journal/newspaper |
| Περιγραφή αρχείου: | ELETTRONICO |
| Γλώσσα: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/38858818; info:eu-repo/semantics/altIdentifier/wos/WOS:001287525900001; volume:40; issue:2; firstpage:308; lastpage:319; numberofpages:12; journal:NEPHROLOGY DIALYSIS TRANSPLANTATION; https://hdl.handle.net/11585/1018002; https://academic.oup.com/ndt/article/40/2/308/7690802 |
| DOI: | 10.1093/ndt/gfae132 |
| Διαθεσιμότητα: | https://hdl.handle.net/11585/1018002 https://doi.org/10.1093/ndt/gfae132 https://academic.oup.com/ndt/article/40/2/308/7690802 |
| Rights: | info:eu-repo/semantics/openAccess ; license:Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY) ; license uri:iris.PUB15 |
| Αριθμός Καταχώρησης: | edsbas.9BAB5C89 |
| Βάση Δεδομένων: | BASE |
καταχωρήστε σχόλιο πρώτοι!